TY - JOUR
T1 - Pharmacokinetic study of 7 compounds following oral administration of Fructus Aurantii to depressive rats
AU - Zhang, Xianhua
AU - Han, Linran
AU - Liu, Jin
AU - Xu, Qiuyue
AU - Guo, Yuxin
AU - Zheng, Wan
AU - Wang, Jian
AU - Huang, Xi
AU - Ren, Ping
N1 - Funding Information:
This project was funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (integration of Chinese and Western medicine) and high-level talents of Nanjing University of Chinese Medicine. It was also supported by National Natural Science Foundation of China (Nos. 81573797, 81072967, and 81373855).
Publisher Copyright:
© 2018 Zhang, Han, Liu, Xu, Guo, Zheng, Wang, Huang and Ren.
PY - 2018/3/5
Y1 - 2018/3/5
N2 - In the present study, the pharmacokinetics of multi-components (naringenin, nobiletin, meranzin hydrate, narirutin, naringin, hesperidin, and neohesperidin) were investigated in acute depressive rats following oral administration of Fructus Aurantii (Zhi-Qiao, ZQ) extract (20 g/kg). A rapid and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was established to quantitatively or qualitatively analyze the 7 absorbed ingredients in the plasma, hippocampus and cortex of acute depressive rats. Biological samples were separated on a 300SB-C18 column, and the 7 compounds were detected with sequential positive and negative ionization modes. Our results confirmed that ZQ has antidepressant effects by decreasing the immobility time. In addition, this validated method showed good linearity (r = 0.9987), and the lower limits of quantification were 2.73-16.38 ng/mL for the 7 analytes. This method successfully determined the pharmacokinetics of the 7 compounds and separated two pairs of isomers in plasma of acute depressive rats following oral administration of ZQ extracts. The 7 active ingredients were also identified as marked compounds in target tissues and should be further examined in pharmacokinetic studies with acute depressive rats. So, pharmacokinetic compounds were precisely linked with the antidepressant effect of ZQ in our study. This relationship is well-understood and contributes to the application of Traditional Chinese Medicine (TCM).
AB - In the present study, the pharmacokinetics of multi-components (naringenin, nobiletin, meranzin hydrate, narirutin, naringin, hesperidin, and neohesperidin) were investigated in acute depressive rats following oral administration of Fructus Aurantii (Zhi-Qiao, ZQ) extract (20 g/kg). A rapid and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was established to quantitatively or qualitatively analyze the 7 absorbed ingredients in the plasma, hippocampus and cortex of acute depressive rats. Biological samples were separated on a 300SB-C18 column, and the 7 compounds were detected with sequential positive and negative ionization modes. Our results confirmed that ZQ has antidepressant effects by decreasing the immobility time. In addition, this validated method showed good linearity (r = 0.9987), and the lower limits of quantification were 2.73-16.38 ng/mL for the 7 analytes. This method successfully determined the pharmacokinetics of the 7 compounds and separated two pairs of isomers in plasma of acute depressive rats following oral administration of ZQ extracts. The 7 active ingredients were also identified as marked compounds in target tissues and should be further examined in pharmacokinetic studies with acute depressive rats. So, pharmacokinetic compounds were precisely linked with the antidepressant effect of ZQ in our study. This relationship is well-understood and contributes to the application of Traditional Chinese Medicine (TCM).
KW - Anti-depression
KW - Fructus Aurantii
KW - Herb
KW - LC/MS/MS
KW - Pharmacokinetic
UR - http://www.scopus.com/inward/record.url?scp=85043336253&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043336253&partnerID=8YFLogxK
U2 - 10.3389/fphar.2018.00131
DO - 10.3389/fphar.2018.00131
M3 - Article
C2 - 29556193
AN - SCOPUS:85043336253
SN - 1663-9812
VL - 9
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
IS - MAR
M1 - 131
ER -